We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Molecular Probe Lights Up Staph Infections

By LabMedica International staff writers
Posted on 17 Feb 2014
A novel chemical probe comprising a self-quenching fluorescently labeled oligonucleotide allows for the rapid, noninvasive detection of staphylococcal (staph) infections.

To more easily identify sites of staph infection investigators at the University of Iowa (Iowa City, USA) created a novel molecular probe. More...
The probe comprised a pair of deoxythymidines flanked by several 2′-O-methyl–modified nucleotides. Various chemical modifications rendered the molecule resistant to mammalian serum nucleases while leaving it susceptible to the action of staphylococcal micrococcal nuclease (MN). A fluorophore was attached to one end of the probe while a molecule that quenched the fluorescence was attached to the other. The presence of the quencher prevented emission of any fluorescent light.

The action of Staphylococcus aureus MN, an endo-exonuclease that digests single-stranded and double-stranded DNA and RNA, digested the probe and liberated the fluorophore from the suppressing effect of the quencher. As the probe was susceptible to digestion only by staph MN, the appearance of fluorescence pinpointed the site of bacterial infection.

The probe's fluorescence was activated in culture supernatants of S. aureus but not in culture supernatants of several other pathogenic bacteria. Systemic administration of this probe to mice bearing S. aureus muscle infections resulted in probe activation at the infection sites in an MN-dependent manner.

"We have come up with a new way to detect staph bacteria that takes less time than current diagnostic approaches," said senior author Dr. James McNamara, assistant professor of internal medicine at the University of Iowa. "It builds on technology that has been around a long time, but with an important twist that allows our probe to be more specific and to last longer. If the probe gets cleaved by serum nucleases, then our probe would be lit up all over the bloodstream. But since it is split only by staph nucleases, then we can pinpoint where the staph bacteria are active."

The investigators applied for US patent to protect use of the molecule in the fall of 2012, and plan to refine the probe so it can be detected deeper in the body and with catheter infections.

A paper describing the novel probe for staph infections was published in the February 2, 2014, online edition of the journal Nature Medicine.

Related Links:

University of Iowa



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.